The Rate of Phosphatase and Tensin (PTEN) Gene Expression Loss in Prostate Cancer and its Link to Tumor Upgrading
Urology Journal,
Vol. 20 (2023),
25 December 2022
,
Page 7412
https://doi.org/10.22037/uj.v20i.7412
Abstract
Purpose: Recent studies have provided reliable evidence for a relationship between loss of PTEN gene expression and prognosis in patients suffering from prostate cancer, although the results have been somewhat diverse in different populations. We aimed to assess PTEN gene expression loss by immunohistochemistry in prostate cancer and also its link to tumor upgrading in a group of affected patients undergoing radical prostatectomy.
Materials and Methods: This cross-sectional study was performed on 58 tissue samples sourced from the patients with prostate cancer and undergoing radical prostatectomy. TRUS-guided needle biopsies of the cancer tissue samples with histological grade groups of I to IV (the Gleason scores of 6 to 8) were prepared as the study samples. 29 patients with Gleason score (6 to 8) whose tumors on needle biopsy upgraded to Gleason score 7, 8 or 9 at prostatectomy (cases) were compared with 29 patients with Gleason scores of 6, 7 or 8 on both biopsy and prostatectomy samples (controls). Immunohistochemistry (IHC) technique was employed to determine PTEN gene expression status.
Results: Loss of PTEN gene expression was found in 62.1% of upgraded cases compared with 27.6% of controls, indicating a statistically significant difference, revealing a meaningful association between the loss of PTEN gene expression and tumor upgrading. Furthermore, we demonstrated that deletions of PTEN gene expression and increased Gleason score in control and upgraded case groups, did not reach statistical significance.
Conclusion: A high rate of PTEN gene expression loss can be detected in prostate cancer tumor tissue, and this loss of gene expression is associated with tumor upgrading.
- Phosphatase and Tensin
- gene
- prostate cancer
How to Cite
References
Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021 ;7:9. doi: 10.1038/s41572-020-00243-0.
Peter A. Humphrey, Holger Moch, Antonio L. Cubilla, Thomas M. Ulbright, Victor E. Reuter. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours, Euro Urol. 2016; 70:106-19. doi.org/10.1016/j.eururo.2016.02.028.
Compérat E, Wasinger G, Oszwald A, Kain R, Cancel-Tassin G, Cussenot O. The Genetic Complexity of Prostate Cancer. Genes (Basel). 2020 ;11:1396. doi: 10.3390/genes11121396.
Turnham DJ, Bullock N, Dass MS, Staffurth JN, Pearson HB. The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer. Cells. 2020 ;9:2342. doi: 10.3390/cells9112342.
Zheng C, Tang F, Min L, Hornicek F, Duan Z, Tu C. PTEN in osteosarcoma: Recent advances and the therapeutic potential. Biochim Biophys Acta Rev Cancer. 2020; 1874:188405. doi: 10.1016/j.bbcan.2020.188405.
Fusco N, Sajjadi E, Venetis K, et al. PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine? Genes (Basel). 2020; 11:719. doi: 10.3390/genes11070719.
Cocco S, Piezzo M, Calabrese A, et al. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int J Mol Sci. 2020; 21:4579.doi: 10.3390/ijms21134579.
Ashrafizadeh M, Zarrabi A, Samarghandian S, Najafi M. PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer? Eur J Pharmacol. 2020; 881:173226. doi: 10.1016/j.ejphar.2020.173226. Epub 2020 May 30.
Chau V, Madan RA, Aragon-Ching JB. Protein kinase inhibitors for the treatment of prostate cancer.ExpertOpinPharmacother.2021;22:1889-99.doi:0.1080/14656566.2021.1925250.
Braglia L, Zavatti M, Vinceti M, Martelli AM, Marmiroli S. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target? Biochim Biophys Acta Mol Cell Res. 2020; 1867:118731.
Maisa Yoshimoto, Olga Ludkovski, Dave DeGrace, et al. PTEN Genomic Deletions that Characterize Aggressive Prostate Cancer Originate Close to Segmental Duplications. GENES, CHROMOSOMES & CANCER. 2012, 51:149-60. doi: 10.1002/gcc.20939.
Lotan TL, Carvalho FL, Peskoe SB, et al. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol. 2015;28:128-37. doi: 10.1038/modpathol.2014.85. Epub 2014 Jul 4. PMID: 24993522; PMCID: PMC4282985.
Ibrahim Kulac 1, Martine P Roudier 2, Michael C Haffner 3. Molecular Pathology of Prostate Cancer. Surg Pathol Clin. 2021; 14:387-401. doi: 10.1016/j.path.2021.05.004. Epub 2021 Jul
Liana B Guedes, Jeffrey J Tosoian, Jessica Hicks, Ashley E Ross, Tamara L Lotan. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy. J Urol. 2017; 197:1054-59. doi: 10.1016/j.juro.2016.09.084. Epub 2016 Sep 28.
C. G. Picanço-Albuquerque, T. Vidotto, C. S. Pereira, et al. PTEN loss in Gleason grade 7 prostate tumors exhibits intratumoral heterogeneity and is associated with unfavorable pathological features. Applied Cancer Research 2019; 39:1
Maisa Yoshimoto 1, Keyue Ding, Joan M Sweet, et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol. 2013; 26:435-47. doi: 10.1038/modpathol.2012.162. Epub 2012 Sep 28.
M E McMenamin 1, P Soung, S Perera, I Kaplan, M Loda, W R Sellers. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999; 59:4291-6.
Güleç Yılmaz, S., Yencilek, F., Yıldırım, A., et al. The Role of Kallikrein10 (KLK10) Polymorphism in Prostate Cancer Susceptibility: KLK10 polymorphism in Prostate Cancer. Urol J. 2021; 19:41-4. doi: 10.22037/uj.v18i.6425
Taghavi, A., Mohammadi-Torbati, P., Kashi, A. H., Rezaee, H., & Vaezjalali, M. Polyomavirus Hominis 1(BK virus) Infection in Prostatic Tissues: Cancer versus Hyperplasia. Urol J. 2015; 12: 2240-44. doi:10.22037/uj.v12i4.2875
- Abstract Viewed: 53 times
- Just Accepted-7412 Downloaded: 33 times